poisar

Stock

BioCryst Pharmaceuticals, Inc. BCRX

$9.43+0.37%

Overview

BCRX market data

Price History

BCRX price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
9.04
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$1.21
Diluted earnings per share over the trailing twelve months.
Beta
0.58
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$6.00 – $11.22
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2.4K · P/B 13.88 · P/S 2.69.

Company news

10 captured
JP Morgan Reinstates Neutral on BioCryst Pharma, Announces $12 Price TargetBenzinga · Jul 13, 2026, 11:06 AM
RBC Capital Maintains Outperform on BioCryst Pharma, Raises Price Target to $14Benzinga · Jul 7, 2026, 3:40 PM
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price TargetBenzinga · Jun 30, 2026, 2:40 PM
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jun 30, 2026, 1:10 PM
Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $29Benzinga · Jun 30, 2026, 12:10 PM
BioCryst Shifts Pipeline Strategy, Reaffirms Sales Outlook Of $635.00M-$660.00M Vs 670.47MBenzinga · Jun 29, 2026, 11:20 AM
8-K filing — BIOCRYST PHARMACEUTICALS INC (BCRX)SEC EDGAR · Jun 29, 2026, 11:06 AM
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual MeetingGlobenewswire Inc · Jun 12, 2026, 11:15 AM
BioCryst Pharmaceuticals Unveiled New Orladeyo Clinical And Real-world Data, Alongside Updated Phase 1b/2 Alpha-star Results For Investigational Hae Therapy NavenibartBenzinga · Jun 12, 2026, 11:10 AM
BioCryst Pharma To Present Seven Abstracts From Hereditary Angioedema Portfolio At Annual Meeting Of EAACI 2026Benzinga · May 27, 2026, 11:25 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock